Management of Positive Margins After Lung Resection

Introduction to Management Strategies

The American Thoracic Society recommends that when clear margins are not achieved during lung resection or bilobectomy, re-resection should be attempted whenever feasible to achieve R0 status, as microscopic residual disease significantly worsens survival in early-stage disease; if re-resection is not possible, adjuvant radiotherapy is indicated for positive margins 1, 2

The European Respiratory Society suggests that intraoperative margin assessment using frozen section or staple line cytology can be performed, though patients with positive cytology typically undergo immediate further resection during the same procedure 3, 4
The American College of Chest Physicians recommends that for sublobar resections, aim for margins >2 cm or at least equal to the tumor diameter (margin-to-tumor ratio ≥1.0) to minimize local recurrence risk, as margins <1 cm are associated with 25% local recurrence versus 6.2% for adequate margins 3, 4
The National Comprehensive Cancer Network advises to avoid extensive tissue undermining or reconstruction until negative margins are confirmed histologically, as this can displace potentially positive margins and complicate re-excision interpretation 5

The European Society for Medical Oncology states that re-excision of the surgical bed should be performed if adequate margins can be achieved with acceptable morbidity, particularly for stage I-II disease where local control directly impacts survival 2, 6
The American College of Radiology recommends that full restaging with MRI of the surgical bed is required to assess for gross residual disease before planning re-resection 2

The American Society for Radiation Oncology indicates that postoperative radiotherapy is indicated for patients with positive resection margins when further resection is not feasible, as there is evidence of benefit in this specific scenario 1
The National Comprehensive Cancer Network suggests that routine postoperative radiotherapy following complete R0 resection is not recommended and may be harmful in stage I-II disease 1, 7
The International Association for the Study of Lung Cancer recommends that for EGFR-mutant stage IB-IIIA NSCLC with R1 resection, adjuvant osimertinib may be considered via extrapolation from ADAURA trial data, particularly given the high risk of relapse with positive margins 2
The American Society of Clinical Oncology advises that adjuvant platinum-based chemotherapy remains strongly recommended for stage IB-IIIA disease regardless of margin status or addition of targeted therapy 2

The Society of Thoracic Surgeons warns to not perform wide undermining or complex reconstruction before confirming negative margins, as this conceals residual tumor and complicates interpretation of subsequent re-excisions 5
The American College of Surgeons notes that the 5-10% rate of patients found inoperable at surgery should not be exceeded; rates above this suggest inadequate preoperative staging 1, 7